Premium
Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?
Author(s) -
Lambers Wietske M.,
Westra Johanna,
Jonkman Marcel F.,
Bootsma Hendrika,
Leeuw Karina
Publication year - 2020
Publication title -
arthritis care and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.032
H-Index - 163
eISSN - 2151-4658
pISSN - 2151-464X
DOI - 10.1002/acr.23894
Subject(s) - medicine , rheumatology , systemic lupus erythematosus , systemic lupus , systemic therapy , clinical trial , disease , systemic disease , intensive care medicine , organ system , cancer , breast cancer
Incomplete systemic lupus ( iSLE ) is an acknowledged condition of patients with clinical signs of lupus who do not fulfill classification criteria for SLE . Some patients with iSLE have persistent mild disease, but others have serious organ involvement, and up to 55% progress to established SLE . Research on this subject could reveal predictive or diagnostic biomarkers for SLE . Ideally, it would become possible to discern those patients with critical organ involvement or a high risk for progression to SLE . This high‐risk group might benefit from early treatment, which would preferably be confirmed in randomized controlled trials. This process would, however, require agreement on a definition of iSLE . The Systemic Lupus International Collaborating Clinics ( SLICC ) classification criteria was composed in order to diagnose SLE earlier. The present review outlines the clinical characteristics of iSLE after introduction of SLICC criteria and furthermore proposes a definition of iSLE with the aim of discriminating the high‐risk group from those with a lower risk.